Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cadonilimab Combined with Chemotherapy in Recurrent/Refractory Pleural Mesothelioma
NCT06416930Phase 2Not yet recruiting
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Start
- Jun 2024
- Primary completion
- Jun 2027
- Modality
- Bispecific Antibodies
01
Overview
Phase 2, open-label, single-arm trial of cadonilimab in pleural mesothelioma, sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences. Primary endpoint: Objective Response Rate at 2 years. Planned start Jun 2024; status: not yet recruiting.
02
Drugs
cadonilimab
03
Conditions
pleural mesothelioma
Beyond the preview
Go deeper on NCT06416930.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06416930.